NCT01776684View on ClinicalTrials.gov

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NAUnknownINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2015

Conditions

EGFR Mutation Positive Non-small Cell Lung Cancer

Interventions

DRUG

EGFR TKIs (gefitinib, erlotinib, afatinib, et al)

Trial Locations (1)

135-710

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER